Pluristem picks CRO for cancer PhI trial, but can’t say who it has chosen


Israeli biotech Pluristem Therapeutics has chosen a “leading, global” CRO to help run its Phase I blood cancer trial--but the company is a little shy on publicity, as it does not want to be named.

In a statement, Pluristem said it is pushing on with the Phase I trial of its experimental treatment using PLX-R18 cells to treat insufficient hematopoietic recovery following hematopoietic cell transplantation by “contracting with a leading global clinical research organization.”

Who? Well, we can’t know. Pluristem told FierceCRO that: “The CRO has a policy not to release their name in publicity by a client, so I am not able to tell you.” So for now, it’s a secret.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

But despite not being in the press release, it will be on hand for the study, which has recently been cleared by the FDA to focus on the safety of the treatment that will consist of intramuscular injections of PLX-R18 cells in 30 patients with incomplete hematopoietic recovery persistent for 6 months or more after HCT. The trial is set to start later this year.

Pluristem Chairman and CEO Zami Aberman said: “Data from this trial will inform the potential of PLX-R18 to treat a wide range of indications including blood cancers and radiation therapy-related blood diseases.”

But Aberman, not able to name names, added: “The CRO we chose has extensive experience working with leading pharmaceutical and biotech companies to successfully manage clinical trials.”

- check out the release

Related Articles:
Pluristem snags spot on EMA's nascent fast-track scheme
Pluristem PLX cells turn around near fatal bone marrow failure

Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.